SuppreMol Appoints Industry Expert Klaus Schollmeier as CEO
4/3/2013 10:05:13 AM
More...
|
SuppreMol Begins Development of Anti-IL-3 Monoclonal Antibody to Diagnose and Treat Early Stage Rheumatoid Arthritis
7/27/2012 10:15:08 AM
More...
|
SuppreMol Releases Positive Interim Phase Ib/IIa Results on SM101 in Primary Immune Thrombocytopenia (ITP) Trials
3/15/2012 9:58:07 AM
More...
|
SuppreMol Employs Protagen AG Biomarkers in SLE Study
8/2/2011 10:05:31 AM
More...
|
SuppreMol Receives U.S. Orphan Drug Designation for SM101
4/23/2010 1:52:15 PM
More...
|
SuppreMol Initiates Phase Ib/Iia Clinical Trial With Its Lead Candidate SM101
4/14/2010 3:27:34 PM
More...
|
SuppreMol Appoints Dr. Robert Phelps as Head of Business Development & Licensing
2/8/2010 12:07:39 PM
More...
|
SuppreMol Announces Start of Phase I Clinical Trial with its lead program SM101
5/11/2009 1:43:50 PM
More...
|
SuppreMol Announces Expansion of its Management Team and Board Changes
10/21/2008 3:28:38 PM
More...
|
SuppreMol Closes EUR 15.7 M Series B Financing Round
7/14/2008 7:04:40 AM
More...
|
|